Key result
Atrial natriuretic peptide (ANP) did not induce cardiac mast cell degranulation or alter cardiac function, indicating it is not responsible for adverse ventricular remodeling in volume overload.
Why the study?
Does atrial natriuretic peptide cause cardiac mast cell degranulation and adverse ventricular remodeling in response to volume overload?
Population
Isolated cardiac mast cells, peritoneal mast cells, blood-perfused isolated rat hearts, and rats with an…
Comparison
Atrial natriuretic peptide infusion or anantin vs Saline-treated controls or sham-operated controls
Design
Preclinical
Authors
Loading...
ANP shows no effect on cardiac mast cells or remodeling in vitro; leaves open alternative pathways in volume overload.
Does atrial natriuretic peptide cause cardiac mast cell degranulation and adverse ventricular remodeling in response to volume overload?
Atrial natriuretic peptide is not a cardiac mast cell secretagogue and does not mediate adverse ventricular remodeling in response to volume overload.
Murray et al. (2007) studied Chronic volume overload. Atrial natriuretic peptide (ANP) vs. Saline-treated controls was evaluated on Cardiac mast cell degranulation and ventricular remodeling. Atrial natriuretic peptide (ANP) did not induce cardiac mast cell degranulation or alter cardiac function, indicating it is not responsible for adverse ventricular remodeling in volume overload.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: